Free tool
FAERS Monitor: Diovan Hct
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020818 or its brand name (Diovan Hct, Hydrochlorothiazide, Valsartan). Reports on generic versions are filed under their own applications.
Reports
13,539
Serious
10,407
77% of reports
Hospitalization
4,212
Death reported
1,385
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- blood pressure increased822
- dizziness803
- hypertension780
- drug ineffective748
- headache712
- fatigue691
- nausea656
- dyspnoea614
- malaise570
- fall561
- pain532
- death501
- diarrhoea466
- cerebrovascular accident446
- asthenia429
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 186 |
| 2005 | 309 |
| 2006 | 343 |
| 2007 | 597 |
| 2008 | 777 |
| 2009 | 1,278 |
| 2010 | 1,089 |
| 2011 | 1,310 |
| 2012 | 1,447 |
| 2013 | 793 |
| 2014 | 647 |
| 2015 | 732 |
| 2016 | 757 |
| 2017 | 521 |
| 2018 | 667 |
| 2019 | 468 |
| 2020 | 394 |
| 2021 | 288 |
| 2022 | 232 |
| 2023 | 222 |
| 2024 | 167 |
| 2025 | 181 |
| 2026 | 134 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,040,620 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| blood pressure increasedSignal | 822 | 8.4 | 7.9 | 5,355 |
| hypertensionSignal | 780 | 5.7 | 5.4 | 3,067 |
| cerebrovascular accidentSignal | 446 | 4.1 | 3.7 | 1,047 |
| fallSignal | 561 | 2.6 | 2.4 | 569 |
| dizzinessSignal | 803 | 2.5 | 2.3 | 740 |
| malaiseSignal | 570 | 2.0 | 1.9 | 299 |
| asthenia | 429 | 1.8 | 1.6 | 146 |
| headache | 712 | 1.8 | 1.6 | 242 |
| dyspnoea | 614 | 1.7 | 1.6 | 175 |
| fatigue | 691 | 1.4 | 1.3 | 74 |
| pain | 532 | 1.3 | 1.2 | 48 |
| nausea | 656 | 1.3 | 1.2 | 44 |
| diarrhoea | 466 | 1.1 | 1.0 | 6 |
| death | 501 | 0.9 | 0.8 | 5 |
| drug ineffective | 748 | 0.9 | 0.8 | 13 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.